NEW YORK (GenomeWeb) – CareFirst BlueCross BlueShield and Myriad Genetics have inked an agreement to conduct an 18-month coverage with evidence development study for Myriad's rheumatoid arthritis test Vectra DA.

The 18-month clinical utility study aims to demonstrate whether Vectra DA — a test that predicts whether a rheumatoid arthritis patient is at risk for radiographic progression — enables rheumatologists to optimize treatment for better patient outcomes and reduces costs compared to conventional approaches.